Inoxgen (Nitric Oxide)

Nitric oxide diffuses into pulmonary vascular smooth‑muscle cells, where it activates soluble guanylate cyclase. This enzyme converts GTP to cyclic GMP, which relaxes smooth muscle, leading to vasodilation confined to the pulmonary circulation while systemic vessels remain largely unaffected.

The prescribed dose of Inoxgen is determined by the treating physician based on the patient’s age, weight, clinical condition, and response to therapy. Dosing is titrated to achieve target pulmonary pressures and is adjusted according to continuous monitoring.

Safety data for inhaled nitric oxide during pregnancy and lactation are limited. Because the drug is administered directly to the lungs and systemic exposure is minimal, it is generally considered low risk, but use should only occur when clearly indicated and under specialist supervision.

To order Inoxgen, submit an inquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Compared with systemic agents such as sildenafil or prostacyclin analogues, inhaled nitric oxide provides rapid, titratable pulmonary vasodilation with minimal systemic hypotension because its effect is confined to ventilated lung regions. This selectivity makes it especially useful in acute settings, though it requires specialized delivery equipment and monitoring.

Inoxgen gas cylinders should be stored at ambient temperature, away from direct sunlight and heat sources. Keep the cylinders in their original packaging, ensure valves are closed when not in use, and handle them according to standard gas safety protocols to prevent accidental release or contamination.

Inoxgen is delivered via a calibrated inhalation system that mixes the gas with the patient’s ventilatory circuit. The gas is administered endotracheopulmonarily, typically through a mechanical ventilator or a specialized delivery mask, allowing precise control of concentration and continuous monitoring of respiratory parameters.

The most serious adverse events associated with inhaled nitric oxide include the development of methemoglobinemia, severe hypotension, rebound pulmonary hypertension upon abrupt discontinuation, and nitrogen dioxide formation which can cause lung injury. Continuous monitoring of methemoglobin levels and careful weaning are essential to mitigate these risks.

Inoxgen should be avoided in patients with known hypersensitivity to nitric oxide or its delivery system, severe anemia, or those receiving high concentrations of other pulmonary vasodilators that could precipitate profound hypotension. Caution is also advised in individuals with significant renal or hepatic impairment, and it is contraindicated where nitrogen dioxide exposure cannot be adequately controlled.